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Alzheimer disease (AD) is characterized by progressive memory loss, reduction in
cognitive functions, and damage to the brain. The β-amyloid precursor protein can be
sequentially cleaved by β- secretase and γ-secretase. Mutations in the presenilin1(PS1)
are the most common cause of Familial Alzheimer’s disease (FAD). PS1 mutations can
alter the activity of γ-secretase on the cleavage of the β-amyloid precursor protein,
causing increased Aβ production. Previous studies show that the βAPP-C-terminal
fragment is first cleaved by β-scretase, primarily generating long fragments of Aβ48
and Aβ49, followed by the stepwise cleavage of every three amino acid residues at
the C terminus, resulting in Aβ48-, 45-, 42 line and Aβ49-, 46-, 43-, 40 line. Here, we
used LC-MS/MS to analyze unique peptides IAT, VVIA, ITL, TVI, IVI through sequential
cleavage, combined with ELISA to test the level of Aβ42 and Aβ40 for validation. The
results show that most FAD mutant PS1 can alter the level of Aβ42 and Aβ40 monitored
by the Aβ42/Aβ40 ratio. Among them, six mutants (I143T, H163P, S170F, Q223R,
M233V, and G384A) affect the Aβ42/40 ratio through both Aβ49-40 and Aβ48-38 lines;
L166P through decreasing the Aβ49-40 line, six mutants (I143V, M146V, G217A, E280A,
L381V, and L392V) through increasing the Aβ48-42 line. More importantly, we found
some mutations can affect the γ-secretase cleavage preference of α-CTF and β-CTF.
In conclusion, we found that the FAD PS1 mutations mainly increase the generation of
Aβ42 by decreasing the cleavage of Aβ42–Aβ38 and Aβ43–Aβ40.
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INTRODUCTION
Alzheimer disease (AD) is the most common neurodegenerative disease. One of the main
etiological hallmarks of AD is excessive production of Aβ (Bentahir et al., 2006; Cacquevel et al.,
2012). Aβ peptides aggregate and deposit into soluble oligomers, fibrils, and senile plaques, which
are closely associated with synaptic dysfunction and neuronal network perturbations, finally
causing gross atrophy of the brain (Lesne et al., 2006; Shankar et al., 2008; Sun et al., 2015).
Aβ is a 38∼43 amino acid peptide derived from the β-APP through sequential cleavage by
β-secretase (BACE1) and γ-secretase (Adlard et al., 2008; Thinakaran and Koo, 2008; Barnwell
et al., 2014). BACE1 is an aspartyl protease β-site APP cleaving enzyme1 that cleaves APP
mainly at a unique site, whereas the γ-secretase complex cleaves the CTF at several sites,
Abbreviations: Aβ, Amyloid β-peptide; APP, amyloid precursor protein; CTF, carboxy-terminal fragments; FAD, Familial
Alzheimer’s disease; PS1, Presenilin1; TMD, transmembrane domains.
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with preference for positions 40 and 42, forming the Aβ1−40 and
Aβ1−42 peptides (Jonsson et al., 2012). Previous studies indicated
that compared to other forms, such as Aβ1−4, Aβ1−38, Aβ1−42,
and Aβ3−40 are more amyloidogenic (Chow et al., 2010). In
particular, Aβ42, which is more prone to aggregate and form
soluble oligomers that eventually form insoluble plaques, is more
amyloidogenic (Kakuda et al., 2006; Czirr et al., 2008). Clinical
studies indicated that Aβ1−42 peptide showed a higher percentage
concentration in AD patients (Burdick et al., 1992; Kim et al.,
2007). In the physiological condition, more than 90% of Aβ is a
shorter form of Aβ40 and less than 5% of Aβ is a longer form of
Aβ42 (Sun et al., 2015).
Autosomal dominant FAD is a rare form of AD and usually
presents before the age of 65 years in individuals with a positive
family history in at least three generations (Wu et al., 2012).
Currently, more than 185 mutations have been identified in PS1,
13 in presenilin 2 (PS2) and 33 in APP among FDA patients
(Cacquevel et al., 2012). PS1 is a trans-membrane protein that
is an important component of the catalytic core of γ-secretase
(Fernandez et al., 2014). γ-secretase, which is a multiprotein
complex, is an unusual intramembranous cleaving aspartyl
protease composed of presenilin, Nicastrin, Pen-2 and Aph-1 (Yu
et al., 2000; Francis et al., 2002; Goutte et al., 2002; Christensen
et al., 2004). PS1 is a highly conservative membrane protein,
with nine TMDs. Large numbers of pathogenic mutations have
been found throughout the coding sequence of PS1. Most of
the PS1 mutations in FAD are located at TMDs (Wanngren
et al., 2014), causing an increase in the Aβ42/Aβ40 ratio,
either by decreasing the production of Aβ40 or increasing the
production of Aβ42 (Bentahir et al., 2006; Shen and Kelleher,
2007; Kretner et al., 2011). Other PS1 mutations in FAD, such
as mutations at D257A and D385A are dominant negative, can
lead to decreased Aβ peptide secretion and the accumulation of
the C-terminal fragments of the precursor protein (Kim et al.,
2001). Previous studies showed that through γ-secretase, βAPP-
C-terminal fragment (β-CTF) is cleaved at the ε-site, generating
primarily long fragments. Meanwhile, Aβ48 and Aβ49 is followed
by stepwise cleavage of every three amino acid residues at the
C terminus (Qi-Takahara et al., 2005). These findings led to
the hypothesis that there are two Aβ product lines: Aβ40 and
Aβ42. In this hypothesis, the Aβ40 product line represents
the amino-terminal APP intracellular domain (AICD) 50–99
and Aβ49, Aβ46, Aβ43, Aβ40, and, the Aβ42 product line
represents AICD 49–99 and Aβ48, Aβ45, Aβ42, Aβ38 (He et al.,
2010).
The PS1 gene has been widely studied since the discovery of
FAD. While initial studies indicated the role of PS1 mutations in
increased Aβ42 production in FAD, it has now become clear that
a series of pathogenic mutations caused impairments in other
PS activities as well, such as Aβ40, AICD, NICD and so on.
Some researchers even proposed that pathogenic mutations in
PS might play a role in the impaired γ-secretase-dependent and
γ-secretase-independent activities through a dominant-negative
mechanism. However, the molecular mechanisms remain elusive
for FAD. Both D257A NTF and D385A CTF have been
shown to abolish the γ-secretase activity in wild type or
pathogenic PS1 mutants (Kim et al., 2005). Other mutations
have also been shown to affect the Aβ42/Aβ40 ratio: eight
mutants (I143T, E280A, P284L, 1exon9, G384A, F386S, S390I,
L392P) were found to increase Aβ42, eleven (I143T, L166P,
A246E, L250S, E280A, P284L, 1exon9, P377M, G384A, L392V)
decrease Aβ40, and twelve (I143T, L166P, A246E, E280A, P284L,
1exon9, R377M, G384A, F386S, S390I, L392P, L392V) decrease
Aβ38. These results show that decreased Aβ38 and Aβ40 and
increased Aβ42 production are common phenotypes of PS1
mutations in FAD. Still more mutations were reported, but
their exact role in FAD are still unclear (Houlden et al.,
2001; Piccini et al., 2007; Uttner et al., 2010; Kim et al.,
2012).
Given the important role the Aβ42/Aβ40 ratio played in
AD, it is very important to understand the mechanism that
leads to this change for the study of amyloidosis processing
and AD onset (Kim et al., 2007). Here, we studied 13
different FAD PS1 mutations, plus one dominant negative
mutation that affects the production of Aβ through APP
processing. We also quantitatively analyzed the triple and tetra
peptide produced by two distinct lines of long amyloid β
cleavage processes with mass spectrometry. Our studies indicate
that different mutations affect the Aβ42/Aβ40 ratio through
different mechanisms. Some decrease the cleavage of Aβ42 to
38 (VVIA), while others decrease the cleavage of Aβ43 to
Aβ40 (IAT). Such results can help us to better understand
the underlying mechanism of PS mutations during the onset
of AD.
MATERIALS AND METHODS
DNA Constructs and Mutagenesis
BACE1-myc-his, pcC99, pcC83, wild-type PS1 human cDNAs
(PS1-WT) were obtained from Weihong Song lab (University
of British Columbia, Vancouver, BC, Canada). Mutations
in PSEN1, (namely, I143T, I143V, M146V, H163P, L166P,
S170F, G217A, M233V, Q223R, E280A, L381V, G384A, D385A,
and L392V) were generated by overlap extension PCR on
the plasmid pcDNA4.1/PS1-WT using corresponding primers
(Supplementary Table S1). The PCR fragments were then
digested using EcoRI /HindIII, and subcloned into pcDNA4.1.
Cell Culture and Transfection
Human embryonic kidney 293 (HEK 293) cells, stably expressing
“Swedish” mtAPP695 and BACE1 (2EB2 cell line), were cultured
in Dulbecco’s Modified Eagle Media, which is a Nutrient
Mixture F-12 (GIBCO, CA) supplemented with 10% fetal
bovine serum (FBS; GIBCO) and 1% penicillin/streptomycin
(GIBCO). Stable cell lines were selected using 200 cug/ml Zeocin
and G418 (Invitrogen). Human embryonic kidney 293 (HEK
293) cells were cultured in Dulbecco’s Modified Eagle Media
(GIBCO, CA) supplemented with 10% FBS (GIBCO) and 1%
penicillin/streptomycin (GIBCO). The cDNA constructs were
transiently transfected into the cells using the Lipofectamine
2000 reagent (Invitrogen), according to the manufacturer’s
instructions.
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Extraction of Tri-, Tetra-, and
Pentapeptides from Living Cultured Cells
2EB2 cells were transfected with PS1 or PS1 with various
mutations. HEK293 cells co-transfected with pcC99 or pcC83
and PS1 or PS1 with various mutations were cultured to
confluence in 10 cm dishes. Protease inhibitors (Protease
inhibitor Cocktail Tablets, Roche, 04693132001) and 1 mM
4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
(AEBSF, sigma, A8456) were added into the conditioned
medium 44 h after transfection. The cells were washed
rapidly with ice-cold PBS, and then, immediately boiled for
2 min. The boiled samples were sonicated for 3 min and
centrifuged. The supernatant was then concentrated using a
speed vacuum concentrator, and finally, subjected to an LC-
MS/MS analysis of the tripeptide and tetrapeptide (Okochi et al.,
2013).
Aβ ELISA
The conditioned medium was collected for an Aβ (Aβ40 and
Aβ42, Invitrogen) level assay. Protease inhibitor and 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride were added
to the conditioned medium 4 h before collection to prevent
degradation of Aβ. The levels of Aβ species (Aβ40 and Aβ42)
were measured by ELISA Kits according to the manufacturer’s
instructions.
Identification and Quantification of
Cleavage Peptides by LC-MS/MS
An electrospray ionization tandem quadruple mass spectrometer,
(Agilent 6460, USA) accompanied by ultra-performance liquid
chromatography (Agilent 1260), was used to identify and
quantify the cleavage peptides. Samples were maintained at 4◦C
in the auto sampler. To quantify each peptide, a combination
of precursor ion product ion pair was monitored using multiple
reaction monitoring (MRM) modes. MRM methods were
measured by LC-MS/MS as described previously (Takami et al.,
2009). The m/z values for these peptides were as follows: 502.7
and 199.2 for VVIAT; 425.7 and 261.2 for FLF; 345.8 and 215.1
for ITL; 329.8 and 185.2 for VIV; 303.7 and 185 for IAT; 331.8
and 185.1 for VIT; 331.8 and 173.1 for TVI; 401.2 and 171.1 for
VVIA.
Immunoblotting
Cells were lysed 48 h after transfection in a RIPA Lysis
Buffer with 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% NP-40, 0.1% SDS, Protease Inhibitor cocktail (Roche)
and AEBSF. Sonication was done using an Ultrasonic Cell
Disruptor (Sonics). The lysates were centrifuged at 14000 g
for 10 min at 4◦C. The protein levels were determined by
the Quick StartTM Bradford protein assay (Bio-Rad, 500-
0201). Cell lysate was subjected to SDS polyacrylamide gel
electrophoresis (SDS-PAGE) with 16% Tris-tricine (Li et al.,
2006; Schagger, 2006) or 10% Tris-glycine gels. The samples
were then transferred to PVDF membranes (Millipore, 0.22 µm).
For protein detection, membranes were blocked for 1 h
with 5% milk, as well as incubated with the polyclonal C20
antibody against the last 20 C-terminus of human APP. The
blots were developed using an ECL system and intensities of
the bands were quantified with Image LabTM Software (Bio-
Rad).
Statistical Analysis
Quantifications were done from data generated during three
independent experiments. Values represent mean ± standard
error of the mean. Comparisons of more than two groups
were carried out using one-way ANOVA and Dunnett’s post
hoc test using PS1 WT values as the control group (Fernandez
et al., 2014). Statistical significance between the two groups
was determined by an unpaired two-tailed t-test. P < 0.05 was
considered to be statistically significant.
RESULTS
Human FAD PS1 Mutations Increase the
Production of CTF
In order to better understand the mechanisms of FAD PS1
mutations, 14 different PS1 mutations were selected and
transiently transfected into 2EB2 cells that stably overexpressed
Swedish APP and BACE1 (Qing et al., 2004). PS1 has nine
TMDs and harbors the catalytic site with two conserved
aspartate residues located in TMD6 and TMD7 (Wolfe et al.,
1999; Henricson et al., 2005; Spasic et al., 2006). It was
reported that most PS1 mutations are located in TMD2, TMD3,
TMD4, TMD5, TMD6, and TMD7. Among them, TMD1-6
and TMD8-9 are hydrophobic. TMD7 has a partial hydrophilic
catalytic cavity and is very sensitive to mutations, which
dramatically reduce its capability to insert into the cell membrane
(Wanngren et al., 2014). TMD7 is part of the hydrophilic
catalytic cavity, which is inserted in the hydrophobic core of
the membrane, and probably protected by stable hydrophobic
domains that include TMD1-6 and TMD8-9. TMD6 is also
susceptible to changes in amino acid residues. Fourteen different
FAD PS1 mutations that we selected are located in TMDs.
Four are located in TMD2 (I143T/V, M146V, H163P); one
in TMD3 (L166P, S170F); one in TMD4 (G217A), two in
TMD5 (Q223R, M233V); one in H7 (E280A); and, three in
TMD7 (L381V, L392V, G384A). One mutant (D385A) was
also used as a negative control (Uttner et al., 2010). Except
for L381V and G384A that have been well-studied, the rest
have rarely, if ever, before been studied. Vector alone, PS1
WT (wild type) or PS1 mutants, were transiently transfected
into 2EB2 cells. Forty-eight hours after transfection, cells were
collected, lysed, and a Western Blot was used to analyze
the expression level of APP and CTFs, especially CTF99
expression. The levels of PS1 expression were used to verify
the transfection efficiency. Compared with the vector alone
(pcDNA4.1), both WT PS1 and PS1 with mutations could
be transfected with high efficiency into the 2EB2 cell line.
While the negative control mutation (D385A) did not affect the
level of APP CTF expression, others, especially I143T, S170F,
M233V, and L392V, increased the expression of APP CTF
(Figures 1A–C).
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FIGURE 1 | Familial Alzheimer’s disease PS1 mutations affect CTF level. Expression levels of APP, CTF in 2EB2 cells expressing empty vector, PS1 WT,
I143T, I143V, M146V, H163P, L166P, S170F, G217A, Q223R, M233V, E280A, L381V, G384A, D385A, L392V. (A) Cell lysates from human Swedish mutant APP695
and BACE1 double expression stable cell line 2EB2 were analyzed by Western Blot. APP, APP CTFs were detected with the C20 polyclonal antibody, PS1-NT was
detected with the rat anti-presenilin-1 monoclonal antibody (Millipore, MAB1563). (B) Quantification of APP in 2EB2 cells in (A). (C) Quantification of C99 in 2EB2
cells in (A). ∗P < 0.05; ∗∗P < 0.01.
FIGURE 2 | Effects of PS1 WT and PS1 Mutants on long Aβ Cleavage in 2EB2 cell line by ELISA (A,B). Conditioned medium from 2EB2 cells expressing
empty vector, PS1-WT or FAD PS1 mutants were analyzed for levels of secreted Aβ40 and Aβ42 using ELISA kit. (A) The levels of Aβ40 and Aβ42 are plotted in
relative to PS1 WT. (B) The Aβ42/Aβ40 ratio. ∗P < 0.05; ∗∗P < 0.01.
Human FAD PS1 Mutations Influence
APP Cleavage Process
To investigate the effect of human FAD PS1 on the APP cleavage
process, empty vector (pcDNA4.1), PS1 WT or PS1 mutants
were again transiently transfected into 2EB2 cells. Forty-eight
hours after transfection, both the conditional medium and the
cells were collected. ELISA was used to measure the levels of
Aβ42 and Aβ40 in the conditional medium. Cells were lysed and
the small peptides (tripeptide and tetrapeptide) were measured
using LC-MS/MS (Agilent 6460, USA). ELISA results showed that
compared to PS1 WT, the dominant negative mutation (D385A)
did not affect the expression levels of Aβ42 and Aβ40, while
most FAD PS1 mutants showed an increased Aβ42/Aβ40 ratio
through different lines. For example, L166P increased the ratio
of Aβ42/Aβ40 by lowering the level of Aβ40. I143V, M146V,
G217A, E280A, L381V, and L392V increased the Aβ42/Aβ40 ratio
through increased expression of Aβ42. The rest of the mutations
increased the ratio of Aβ42/Aβ40 through both decreasing Aβ40
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and increasing Aβ42 levels at the same time (Figures 2A,B).
The amounts of tripeptide and tetrapeptide produced during
the stepwise processing of longer form Aβ in living cells were
then measured (Figures 3 and 4). The result indicated that
neither the negative control nor any of the selected FAD PS1
mutations affected the selectivity of the γ-secretase cleavage of
long form Aβ, judged by the total level of Aβ49-40 relative to
that of total Aβ-related small peptides (Figure 4A). Compared
to the PS1-WT, except for L166P and D385A mutations, most
PS1 mutations were able to reduce the relative rate of Aβ42
cleavage into Aβ38. This reduction was concluded based upon
the level of VVIA relative to that of total Aβ48-42 related small
peptides (Figure 4B). Correspondingly, compared with PS1-
WT, most FAD PS1 mutations (I143T, H163P, L166P, S170F,
Q223R, M233V, E280A, and G384A) were able to decrease
the relative rate of Aβ43 cleavage into Aβ40. This finding
is based upon the level of IAT relative to that of the total
Aβ49-40 related small peptides (Figure 4C). The LC-MS/MS
results are consistent with the results from ELISA and Western
Blot.
FIGURE 3 | Detection of related small peptide species of Aβ. (A) The chromatographys of IAT standard peptides. (B) The Intensity of multiple reactions
monitoring (MRM) ion chromatography of ITA. (1) Its transition is m/z = 303.7/185. Black, pCDNA4.1; Red, PS1; Blue, M233V. (C) The chromatographys of VVIA
standard peptides. (D) The Intensity of multiple reactions monitoring (MRM) ion chromatography of VVIA. (2) Its transition is m/z = 401.2/171.1. Black, pCDNA4.1;
Red, PS1; Blue, M233V. (E) Aβ species in lysates of 2EB2 cells in a 10 cm dish overexpressing PS1 WT.
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FIGURE 4 | Effects of PS-WT1 and PS1 Mutants on long Aβ Cleavage in 2EB2 cell line by LC-MS/MS. (A) Fold changes of the relative rate of Aβ49-40/total
Aβ production. (B) Fold changes of the relative VVIA levels in cell lysates of 2EB2 cell line. (C) Fold changes of the relative IAT levels in cell lysates of 2EB2 cells line.
(D) Fold changes of the relative VIT, TVI, and VVIA levels in cell line expressing PS1 and PS1 FAD mutants. (E) Fold changes of the relative ITL, VIV, and IAT levels in
cell line expressing PS1 and PS1 FAD mutants. ∗P < 0.05; ∗∗P < 0.01.
Human FAD PS1 Mutations Differ in Their
Effect on Aβ Generated by β-CTF Line
Amyloid precursor protein can be cleaved into α-CTF (CTF83)
and β-CTF (CTF99) by α-secretase and β-secretase in vivo,
respectively. Therefore, we want to examine whether CTF83 can
affect the CTF99 cleavage with PS1 mutations. pzC99, which is
the cDNA encoding CTF99, was inserted into the pcDNA4.1
vector. We co-transfected transiently pzC99 with the empty
vector, PS1 WT or PS1 mutants, into HEK293 cells. Forty-
eight hours after transfection, both the condition medium and
the cells were collected. The levels of Aβ42 and Aβ40 in the
culture medium were similar to the previous ELISA results
(Figures 2A,B). Most FAD PS1 mutations also increased the
ratio of Aβ42/Aβ40 as shown before: L166P increased the ratio
of Aβ42/Aβ40 by reducing Aβ40 level; I143V, M146V, G217A,
E280A, L381V, and G384 increased the ratio of Aβ42/Aβ40 by
increasing Aβ42 level; and finally, the rest of the mutations
increased the ratio of Aβ42/Aβ40 by both reducing Aβ40 and
increasing Aβ42 levels (Figures 5A,B). Cells were then lysed and
the tripeptide and tetrapeptide were measured using LC-MS/MS
(Figure 3). The results were in agreement with previous results
in the Aβ48–Aβ38 line (Figure 4D). Compared with PS1-WT,
some FAD PS1 mutations (I143T, I143V, M146V, H163P, S170F,
G217A, Q223R, M233V, E280A, L381V, G384A, and L392V),
showed elevated levels of Aβ42 as a result of lower VVIA, which
was produced by the cleavage of Aβ42 into Aβ38, L166P and
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FIGURE 5 | Effects of PS1-WT and PS1 Mutant on CTF99 Cleavage. (A,B) Conditioned medium from HEK293 co-expressing pzC99-flag and PS1-WT or FAD
PS1 mutations were analyzed for levels of secreted Aβ40 and Aβ42 species using ELISA kit. (A) The levels of Aβ40 and Aβ42 are plotted in relative to PS1 WT.
(B) The Aβ42/Aβ40 ratio. (C) Fold changes of the relative VVIA levels in cell lysates of HEK293 transfected pzC99 and PS1/PS1 FAD mutations. (D) Fold changes of
the relative IAT levels in cell lysates of HEK293 transfected pzC99 and PS1/PS1 FAD mutations. (E) Fold changes of the relative VIT, TVI, and VVIA levels in cell
lysates of HEK293 transfected pzC99 and PS1/PS1 FAD mutations. (F) Fold changes of the relative ITL, VIV, and IAT levels in cell lysates of HEK293 transfected
pzC99 and PS1/PS1 FAD mutations. ∗P < 0.05; ∗∗P < 0.01.
negative control had no effect on the VVIA level (Figure 5C).
The results of Aβ49–Aβ40 line were slightly different (Figure 4E).
Some FAD PS1 mutations (I143T, M146V, H163P, L166P, S170F,
Q223R, M233V, E280A, L381V, and L392V) secreted lower levels
of Aβ40, causing a lower level of IAT to be generated by the
cleavage of Aβ43 into Aβ40. Others, such as I143V, G217A, and
G384A, as well as the negative control, did not affect the IAT
levels (Figure 5D). Among them, M146V, G384A, L381V, and
L392V showed slightly different results from the previous data
(Figures 4B,C). This could be due to CTF83 competing with
CTF99 for cleavage by γ-secretase.
Human FAD PS1 Mutations Differ in Their
Effect on Aβ by α-CTF Line
The above results showed that FAD PS1 mutations differ in
their effects on the Aβ generation line of APP and CTF99,
especially in the Aβ49–Aβ40 line. APP could be cleaved by
different secretase to generate α-CTF and β-CTF. Subsequently,
they could be sequentially cleaved to produce Aβ fragments
using γ-secretase. Both α-CTF and β-CTF can give rise to
the tri- and tetra-peptides, but only β-CTF can eventually
generate Aβ42. Thus, we further tested the hypothesis that
the presence of CTF83 may affect the cleavage of CTF99.
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FIGURE 6 | Effects of PS1-WT and PS1 Mutants on CTF83 Cleavage. (A) Fold changes of the relative VVIA levels in cell lysates of HEK293 transfected pzC83
and PS1-WT or FAD PS1 mutations. (B) Fold changes of the relative IAT levels in cell lysates of HEK293 transfected pzC83 and PS1-WT or FAD PS1 mutations.
∗P < 0.05; ∗∗P < 0.01.
FIGURE 7 | Summarize the effects on specific peptides cleaved from long Aβ in different mutations. The APP can be sequential cleavage by β-secretase
(BACE1)/α-secretase and γ-secretase. APP-C-terminal fragment is cleaved at the ε-site by γ-secretase, generating primarily long fragments, Aβ48 and Aβ49,
followed by stepwise cleavage of every three amino acid residues at the C terminus, generating unique peptide. PS1 negative control, D385A, showed no change in
unique peptide VVIA and IAT. Six mutations (I143T, H163P, S170F, Q223R, M233V, and G384A) change the ratio of Aβ42/40 by decreasing the cleavage of Aβ43-40
and Aβ42-38. L166P affect the ratio of Aβ42/40 by decreasing the cleavage of Aβ43-40. Six mutations (I143V, M146V, G217A, E280A, L381V, and L392V) affect the
ratio of Aβ42/40 by decreasing the cleavage of Aβ42-38.
ELISA results showed that Aβ42 could not be detected in
either PS1-WT or FAD PS1 mutations. The LC-MS/MS results
showed that compared to PS-WT, some FAD PS1 mutations
(I143T, I143V, H163P, S170F, L381V, and L392V) produced
lower levels of VVIA (Figure 6A). Meanwhile, others (I143T,
H163P, S170F, G217A, M233V, and G384A) produced lower
levels of IAT (Figure 6B). Combined with the data of a specific
peptide IAT cleaved from APP and a β-CTF cleavage using
γ-secretase (Figures 4 and 5), we propose that the existenceof
α-CTF may affect the β-CTF cleavage in certain, (i.e., M146V,
Frontiers in Aging Neuroscience | www.frontiersin.org 8 March 2016 | Volume 8 | Article 51
fnagi-08-00051 March 9, 2016 Time: 18:17 # 9
Li et al. Cleaved A β Forms in Presenilin1 Mutants
L381V, G384A, and L392V) but not all, FAD PS1 mutations.
Moreover, the presence of CTF83 may affect the cleavage of
CTF99.
DISCUSSION
The PS1 mutation is known to be a key heredity factor of FAD.
Mutation in PS1 can cause changes to γ-secretase activities,
resulting in the alteration of the Aβ42/40 ratio. Recent research
data show that Aβ can be generated by a series and continuous
cleavage using γ-secretase (Takami et al., 2009; Okochi et al.,
2013; Olsson et al., 2014). LC-MS/MS can be used to monitor the
cleavage progress by following the tripeptides and tetrapeptides
generated during the process. Based on the Aβ48–Aβ38 and
Aβ49–Aβ40 cleavage lines, 14 PS1 mutations impacting the
Aβ42/40 ratio via different lines of Aβ generated line were
reported. Here, we discovered four significant findings. First,
the PS1 negative control (D385A) showed no change in Aβ42,
Aβ40 level, or Aβ42/40 ratio. This outcome is likely because they
do not affect the cleavage of CTF83 and CTF99, especially the
unique peptide VVIA and IAT. LC-MS/MS results indicated that
they do not significantly affect the CTF83 and CTF99 cleavage
line either. Second, six mutations (I143T, H163P, S170F, Q223R,
M233V, and G384A) change the ratio of Aβ42/40 by decreasing
the level of Aβ40 and increasing the level of Aβ42, respectively.
Meanwhile, the cleavage of Aβ42 to Aβ38 and of Aβ43 to Aβ40
were both decreased. Such results indicate that those mutations
affect the Aβ42/40 ratio through both the Aβ49-40 line and the
Aβ48-42 line. Third, one mutation (L166P) affected the ratio
of Aβ42/40 by decreasing the level of Aβ40 as a result of the
decreased specific cleavage of Aβ43 to Aβ40, with no effect on
Aβ42. This outcome indicates that L166P affects the Aβ42/40
ratio mainly through the Aβ49-40 line. Fourth, six mutations
(I143V, M146V, G217A, E280A, L381V, and L392V) affected the
ratio of Aβ42/40 by increasing the level of Aβ42, via specifically
decreasing the cleavage of Aβ42 to Aβ38, with no effect on Aβ40.
This outcome suggests that those mutations affect the Aβ42/40
ratio mainly through the Aβ48–Aβ40 line. To summarize, except
for the negative control (D385A), which showed no effect on the
Aβ42/40 ratio and the process of β-CTF cleavage, most of PS1
mutations could change the Aβ42/40 ratio through different long
form Aβ cleavage lines (Figure 7).
Exactly how FAD mutations lead to the AD neuropathogenesis
is still a mystery at present. One prevailing hypothesis is that
PS mutations in mammalian systems cause the increase of the
γ-secretase activity and enhance Aβ42 production (Shioi et al.,
2007). Conversely, some new studies suggest that some mutations
in FAD PS1 mutations (i.e., V82L, C263R et al.) not only
would not increase production of Aβ42, but also lead to a loss
of its essential functions. Many studies showed that FAD PS1
mutations would increase the ratio of Aβ42/Aβ40. However,
previous studies primarily focus on, the lowered production
of Aβ40, rather than the increased production of Aβ42 (Shen
and Kelleher, 2007). Our data seems to be in agreeing with
the previous hypotheses. Here, we show that L166p impacts
the Aβ42/Aβ40 ratio by decreasing the level of Aβ40, rather
than increasing the level of Aβ42 corresponds with previous
work. Three PS1 mutations (L133P, G183V, and insR352) were
found to cause a lack of amyloid pathology (Raux et al., 2000;
Amtul et al., 2002; Dermaut et al., 2004) and an absence of Aβ
accumulation. Such mutations are believed to be associated with
Frontotemporal Dementia (FTD) more than with FAD, despite
the fact they can be found in both FAD and FTD patients. The
data we collected leads us to believe that most FAD PS1 mutations
lead to amyloid pathogenesis. This outcome maybe due to FAD
PS1 mutations function in regulating the cleavage of Aβ42–Aβ38
and Aβ43–Aβ40.
Interestingly, our results indicated that PS1 mutations have
different effects on the β-CTF and APP processing of Aβ
generation. It is known that APP can be cleaved by β-secretase
and α-secretase, generating β-CTF and α-CTF. Subsequently,
α-CTF and β-CTF may both be cleaved by γ-secretase.
Additionally, α-CTF may remain the same peptide through the
processing of γ-secretase cleavage. Here, we detected tri-peptides
and tetra-peptides in the HEK293 cell linings co-transfected with
the PS1 mutation and CTF83. We found that α-CTF is also
processed by a series of continuous cleavages that produce the
same tri-peptides and tetra-peptides as that of β-CTF. Moreover,
the PS1 mutation could alter the cleavage process of α-CTF as
well. Some mutations have different effects on the processing of
α-CTF and β-CTF cleavages, suggesting that changes in the PS1
structure may decrease a β-CTF cleavage with no effect on α-CTF.
CONCLUSION
Most mutations in PS1 accelerate the amyloid formation by
affecting the Aβ generation process that results in a change of
Aβ42/40 in FAD causing dementia.
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